Who Paid My Doc
Elias Sarkis
Child & Adolescent Psychiatry Gainesville, FL Medical Doctor
NPI 1285749283 CMS profile 239756
529 Nw 60Th St, Gainesville, FL 32607
General payments
$168,625
Research payments
$111,056
Ownership & investment interest
$0
Research they led as principal investigator
$3,789,831
Through program year 2025, Elias Sarkis of Gainesville, FL is reported in the CMS Open Payments database as having received $168,625 across 787 general payments and $111,056 in research payments paid to them. Separately, studies naming them as principal investigator received $3,789,831 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $34,500 | 93 | |
| 2024 | General | $29,256 | 98 | |
| 2023 | General | $18,483 | 93 | |
| 2023 | Research | $3,600 | 2 | |
| 2022 | General | $21,189 | 114 | |
| 2021 | General | $6,970 | 111 | |
| 2021 | Research | $4,157 | 1 | |
| 2020 | General | $16,210 | 84 | |
| 2020 | Research | $18,390 | 3 | |
| 2019 | General | $42,015 | 194 | |
| 2019 | Research | $84,909 | 12 |
Beside peers
- Elias Sarkis
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Elias Sarkis were reported at $34,500. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Elias Sarkis | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $42,015 | $129 | $42–$419 | $163 |
| 2020 | $16,210 | $81 | $28–$226 | $114 |
| 2021 | $6,970 | $115 | $31–$326 | $132 |
| 2022 | $21,189 | $124 | $40–$382 | $149 |
| 2023 | $18,483 | $130 | $45–$420 | $160 |
| 2024 | $29,256 | $141 | $42–$490 | $164 |
| 2025 | $34,500 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
527
Drug cost
$10,878
Branded share of claims
24.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dextroamphetamine Sulfate Er Dextroamphetamine Sulfate | Brand | 12 | $1,493 | |
| Gabapentin | Generic | 34 | $1,326 | |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | Brand | 16 | $1,202 | |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 43 | $1,105 | |
| Methylphenidate Er Methylphenidate Hcl | Brand | 19 | $789 | |
| Bupropion Xl Bupropion Hcl | Brand | 37 | $721 | |
| Clonazepam | Generic | 68 | $608 | |
| Ziprasidone Hcl | Generic | 12 | $562 | |
| Lorazepam | Generic | 44 | $505 | |
| Risperidone | Generic | 24 | $497 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 17 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Qelbree |
|
$28,156 | — | — |
| VRAYLAR |
|
$254 | — | — |
| Auvelity |
|
$229 | — | — |
| JORNAY PM |
|
$163 | — | — |
| TRINTELLIX |
|
$75 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 17 in the dashboard with a free accountRecords
805 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Child & Adolescent Psychiatry in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.